

Krista L Lanctôt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/968888/krista-l-lanctot-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

315 papers	14,239 citations	57 h-index	110 g-index
333 ext. papers	16,771 ext. citations	4.5 avg, IF	6.47 L-index

#	Paper	IF	Citations
315	Pharmacological Management of Apathy in Dementia.. <i>CNS Drugs</i> , 2022 , 1	6.7	0
314	Time setting errors in the Clock Drawing Test are associated with both semantic and executive deficits.. <i>Applied Neuropsychology Adult</i> , 2022 , 1-10	1.9	1
313	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	5
312	Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment: a meta-analysis.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 23	9	2
311	Therapeutic Passes and Post-Discharge Outcomes in a Psychiatric Inpatient Unit: A Retrospective Study.. <i>Canadian Journal of Psychiatry</i> , 2022 , 7067437221087945	4.8	
310	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 48	9	4
309	Cognitive control, interference inhibition, and ordering of information during working memory in younger and older healthy adults.. <i>GeroScience</i> , 2022 , 1	8.9	
308	Questioning the Meaning of a Change on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time. <i>Assessment</i> , 2021 , 28, 1708-1722	3.7	2
307	Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. <i>Neurochemistry International</i> , 2021 , 152, 105250	4.4	1
306	Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects.. <i>Drugs and Aging</i> , 2021 , 39, 153	4.7	3
305	Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2021 , 100, 55-69	16.6	3
304	Impact of 12-week exercise program on biomarkers of gut barrier integrity in patients with coronary artery disease. <i>PLoS ONE</i> , 2021 , 16, e0260165	3.7	1
303	The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases. <i>Molecular and Cellular Neurosciences</i> , 2021 , 117, 103683	4.8	1
302	Mirtazapine for agitation in dementia: moving forward. <i>Lancet, The</i> , 2021 , 398, 1462-1463	40	1
301	Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. <i>Ageing Research Reviews</i> , 2021 , 72, 101499	12	2
300	Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers. <i>Psychoneuroendocrinology</i> , 2021 , 134, 105448	5	4
299	A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. <i>American Journal of Perinatology</i> , 2021 , 38, e129-e136	3.3	

298	Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder. <i>International Psychogeriatrics</i> , 2021 , 1-7	3.4	1
297	Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. <i>American Journal of Perinatology</i> , 2021 ,	3.3	2
296	Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2021 , 126, 105149	5	7
295	Diagnostic criteria for apathy in neurocognitive disorders. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	18
294	Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 51-62	6.5	12
293	Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 81-89	6.5	4
292	Depression and Increased Risk of Alzheimer's Dementia: Longitudinal Analyses of Modifiable Risk and Sex-Related Factors. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 917-926	6.5	2
291	The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. <i>Journal of Affective Disorders</i> , 2021 , 280, 140-147	6.6	1
290	Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. <i>Neurobiology of Aging</i> , 2021 , 100, 22-31	5.6	4
289	The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε carrier status. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 43	9	8
288	Glutathione Peroxidase Activity Is Altered in Vascular Cognitive Impairment-No Dementia and Is a Potential Marker for Verbal Memory Performance. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1285-1296	4.3	1
287	Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2021 ,	6.5	5
286	Assessing the Longitudinal Relationship between Theta-Gamma Coupling and Working Memory Performance in Older Adults. <i>Cerebral Cortex</i> , 2021 ,	5.1	2
285	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 1324-1332	17.2	6
284	Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease. <i>BMC Geriatrics</i> , 2021 , 21, 677	4.1	0
283	Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: A stratified longitudinal observational study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041312	1.2	0
282	Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: Longitudinal associations with PET amyloid in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042014	1.2	
281	Investigating the relationship between neuropsychiatric symptoms and cognition in mild cognitive impairment and Alzheimer's disease patients undergoing an exercise-primed transcranial direct current stimulation clinical trial (The EXPRESS Study). <i>Alzheimer's and Dementia</i> , 2020 , 16, e046158	1.2	

280	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020 , 10, 152	8.6	48
279	Endostatin as a Mediator Between Endothelial Function and Cognitive Performance in Those at Risk for Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 601-611	4.3	3
278	A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020 , 17, 84	10.1	13
277	Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020 , 267, 185-190	6.6	7
276	Attentional impairments to novel images in dementia 2020 , 597-616		
275	Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020 , 75, 671-679	6.4	9
274	A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Journal of ECT</i> , 2020 , 36, 211-215 ²		8
273	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1143-1156	4.3	17
272	Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 1256-1269	6.5	15
271	Serum osteocalcin is associated with subjective stress in people with depression and type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2020 , 122, 104878	5	0
270	Depression and Diabetes Mellitus Multimorbidity Is Associated With Loss of Independence and Dementia Poststroke. <i>Stroke</i> , 2020 , 51, 3531-3540	6.7	5
269	Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017). <i>Pediatric Infectious Disease Journal</i> , 2020 , 39, 539-545	3.4	3
268	Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study. <i>Pediatric Infectious Disease Journal</i> , 2020 , 39, 694-699	3.4	4
267	Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. <i>Ageing Research Reviews</i> , 2020 , 62, 101130	12	6
266	Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1663-1673	1.2	18
265	: Mood, Cognition and Fatigue following Stroke, 6th edition update 2019. <i>International Journal of Stroke</i> , 2020 , 15, 668-688	6.3	51
264	Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020 , 33, 175-184	3.8	16
263	24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 21-31	4.3	7

262	The value of screening for cognition, depression, and frailty in patients referred for TAVI. <i>Clinical Interventions in Aging</i> , 2019 , 14, 841-848	4	6
261	Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1561-1568	5.3	1
260	Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 1161-1173	6.5	46
259	Validity of a novel screen for cognitive impairment and neuropsychiatric symptoms in cardiac rehabilitation. <i>BMC Geriatrics</i> , 2019 , 19, 163	4.1	3
258	Plasma Sphingolipids Mediate a Relationship Between Type 2 Diabetes and Memory Outcomes in Patients with Coronary Artery Disease Undertaking Exercise. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 717-727	4.3	4
257	Lithium Carbonate in a Poststroke Population: Exploratory Analyses of Neuroanatomical and Cognitive Outcomes. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 67-71	1.7	7
256	Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. <i>Drugs and Aging</i> , 2019 , 36, 589-605	4.7	15
255	The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 873-882	6.5	37
254	The Role of Apathy and Depression on Verbal Learning and Memory Performance After Stroke. <i>Archives of Clinical Neuropsychology</i> , 2019 , 34, 327-336	2.7	7
253	Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer's Disease. <i>Current Behavioral Neuroscience Reports</i> , 2019 , 6, 72-87	1.7	1
252	Younger Age and Depressive Symptoms Predict High Risk of Generalized Anxiety After Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2019 , 50, 2359-2363	6.7	12
251	Association Between Endothelial Function and Cognitive Performance in Patients With Coronary Artery Disease During Cardiac Rehabilitation. <i>Psychosomatic Medicine</i> , 2019 , 81, 184-191	3.7	6
250	Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2019 , 15, 100385	1.8	12
249	Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attack. <i>Psychiatry Research</i> , 2019 , 279, 361-363	9.9	10
248	Sleep and Attention in Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2019 , 92, 53-61	2.4	5
247	Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	17
246	Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2019 , 38, 775-780	3.4	3
245	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019 , 15, 292-312	1.2	155

244	Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017. <i>Clinical Infectious Diseases</i> , 2019 , 69, 980-986	11.6	6
243	Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders. <i>European Journal of Pediatrics</i> , 2019 , 178, 377-385	4.1	5
242	Screening for Post-Stroke Depression and Cognitive Impairment at Baseline Predicts Long-Term Patient-Centered Outcomes After Stroke. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019 , 32, 40-48	3.8	21
241	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. <i>Molecular Neurobiology</i> , 2018 , 55, 4195-4206	6.2	200
240	Suicide deaths by intentional self-poisoning in people with cardiovascular disease. <i>General Hospital Psychiatry</i> , 2018 , 52, 41-47	5.6	6
239	The effect of white matter hyperintensities on verbal memory: Mediation by temporal lobe atrophy. <i>Neurology</i> , 2018 , 90, e673-e682	6.5	24
238	Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. <i>Current Opinion in Psychiatry</i> , 2018 , 31, 140-146	4.9	14
237	Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 1113-1118	5.3	7
236	An International Approach to Enhancing a National Guideline on Driving and Dementia. <i>Current Psychiatry Reports</i> , 2018 , 20, 16	9.1	16
235	Subcortical hyperintensities in the cholinergic system are associated with improvements in executive function in older adults with coronary artery disease undergoing cardiac rehabilitation. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 279-287	3.9	6
234	Prevalence, neurobiology, and treatments for apathy in prodromal dementia. <i>International Psychogeriatrics</i> , 2018 , 30, 177-184	3.4	24
233	Social inappropriateness in neurodegenerative disorders. <i>International Psychogeriatrics</i> , 2018 , 30, 197-207	3.4	40
232	Global grey matter volume in adult bipolar patients with and without lithium treatment: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018 , 225, 599-606	6.6	43
231	Apathy, not depressive symptoms, as a predictor of semantic and phonemic fluency task performance in stroke and transient ischemic attack. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018 , 40, 449-461	2.1	13
230	Psychometric properties of apathy scales in Parkinson's disease: a systematic review. <i>Neurodegenerative Disease Management</i> , 2018 , 8, 267-282	2.8	5
229	Detection of Apathy in Alzheimer Patients by Analysing Visual Scanning Behaviour with RNNs 2018 ,		5
228	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial. <i>BMC Geriatrics</i> , 2018 , 18, 27	4.1	7
227	Pharmacological interventions for apathy in Alzheimer's disease. <i>The Cochrane Library</i> , 2018 , 5, CD012193	3.2	37

226	Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. <i>Journal of Clinical Psychiatry</i> , 2018 , 80,	4.6	14
225	Cognitive Outcomes After Transcatheter Aortic Valve Implantation: A Metaanalysis. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 254-262	5.6	13
224	Adherence and outcomes: a systematic review of palivizumab utilization. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 27-42	3.8	19
223	F4-02-04: NABILONE SIGNIFICANTLY IMPROVES AGITATION/AGGRESSION IN PATIENTS WITH MODERATE-TO-SEVERE AD: PRELIMINARY RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND, CROSS-OVER TRIAL 2018 , 14, P1385-P1385		5
222	Effect of Methylphenidate for Apathy on Visual Attention Scanning Behavior: a Pilot Study. <i>Canadian Geriatrics Journal</i> , 2018 , 21, 139-142	2.8	1
221	Psychometric Properties of Apathy Scales in Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1065-1082	4.3	15
220	Longitudinal associations between 4-hydroxynonenal and depression in coronary artery disease patients. <i>Psychiatry Research</i> , 2018 , 270, 219-224	9.9	3
219	The effect of exercise on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF) in major depressive disorder: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2018 , 105, 123-131	5.2	20
218	Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 1235-1246	4.3	7
217	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	8
216	Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1344-1376	1.2	23
215	Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimer's and Dementia</i> , 2017 , 13, 84-100	1.2	127
214	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 929-938	4.3	182
213	Ceramides and depression: A systematic review. <i>Journal of Affective Disorders</i> , 2017 , 213, 35-43	6.6	30
212	Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). <i>Pediatric Infectious Disease Journal</i> , 2017 , 36, 445-450	3.4	13
211	The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysis. <i>European Journal of Neuroscience</i> , 2017 , 46, 1635-1646	3.5	135
210	"Good Outcome" Isn't Good Enough: Cognitive Impairment, Depressive Symptoms, and Social Restrictions in Physically Recovered Stroke Patients. <i>Stroke</i> , 2017 , 48, 1688-1690	6.7	68
209	Update on the Risk of Motor Vehicle Collision or Driving Impairment with Dementia: A Collaborative International Systematic Review and Meta-Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 1376-1390	6.5	22

208	Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer's disease: A preliminary report. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 7, 56-60	5.2	28
207	Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2017 , 7, 317-329	2.8	16
206	Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2017 , 36, 2-8	3.4	22
205	Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 876-882	5.5	199
204	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 440-449	6	153
203	A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 829-841	4.3	15
202	First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). <i>European Journal of Pediatrics</i> , 2017 , 176, 413-422	4.1	9
201	Peripheral lipid oxidative stress markers are related to vascular risk factors and subcortical small vessel disease. <i>Neurobiology of Aging</i> , 2017 , 59, 91-97	5.6	22
200	Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. <i>Brain, Behavior, and Immunity</i> , 2017 , 60, 136-141	16.6	20
199	Plasma sphingolipids and depressive symptoms in coronary artery disease. <i>Brain and Behavior</i> , 2017 , 7, e00836	3.4	13
198	Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 885-896	4.3	8
197	[P3010]: PLASMA SPHINGOLIPID RATIOS AND VERBAL MEMORY PERFORMANCE IN A CORONARY ARTERY DISEASE POPULATION AT RISK FOR VASCULAR COGNITIVE IMPAIRMENT (VCI) AND ALZHEIMER'S DISEASE 2017 , 13, P1016-P1017		
196	[P3039]: A LIPIDOMICS APPROACH TO ASSESS PLASMA SPHINGOLIPIDS AS PREDICTORS OF VERBAL MEMORY PERFORMANCE IN CORONARY ARTERY DISEASE PATIENTS UNDERTAKING CARDIAC REHABILITATION: A C18:0 SIGNATURE FOR COGNITIVE RESPONSE TO EXERCISE 2017 , 13, P1031-P1031		
195	[O10106]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS 2017 , 13, P184		
194	Baseline Oxidative Stress Is Associated with Memory Changes in Omega-3 Fatty Acid Treated Coronary Artery Disease Patients. <i>Cardiovascular Psychiatry and Neurology</i> , 2017 , 2017, 3674371		8
193	The "DOC" screen: Feasible and valid screening for depression, Obstructive Sleep Apnea (OSA) and cognitive impairment in stroke prevention clinics. <i>PLoS ONE</i> , 2017 , 12, e0174451	3.7	15
192	Inflammatory Markers and Brain-Derived Neurotrophic Factor as Potential Bridges Linking Bipolar Disorder and Cardiovascular Risk Among Adolescents. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e286-e293	4.6	22
191	Pharmacotherapy of Dementia. <i>Mental Health and Illness Worldwide</i> , 2017 , 455-480	0.1	

190	Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1339-1349	4.3	18
189	Evidence for Inflammation-Associated Depression. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 31, 3-30	3.4	51
188	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease. <i>Neuropsychiatric Disease and Treatment</i> , 2016 , 12, 2913-2920	3.1	8
187	Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2417-2429	4	13
186	O1-13-03: The Mild Behavioral Impairment Checklist (MBI-C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease 2016 , 12, P209-P210		
185	Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. <i>Pediatric Infectious Disease Journal</i> , 2016 , 35, 1187-1193	3.4	3
184	Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 436-44	1.7	24
183	Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. <i>Brain, Behavior, and Immunity</i> , 2016 , 53, 54-58	16.6	5
182	Validating a Pragmatic Approach to Cognitive Screening in Stroke Prevention Clinics Using the Montreal Cognitive Assessment. <i>Stroke</i> , 2016 , 47, 807-13	6.7	13
181	Bias in Peripheral Depression Biomarkers. <i>Psychotherapy and Psychosomatics</i> , 2016 , 85, 81-90	9.4	44
180	Suicide in males and females with cardiovascular disease and comorbid depression. <i>Journal of Affective Disorders</i> , 2016 , 197, 88-93	6.6	11
179	A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 142-7	5.9	37
178	The Effect of Exercise Training on Resting Concentrations of Peripheral Brain-Derived Neurotrophic Factor (BDNF): A Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0163037	3.7	134
177	The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2016 , 22, 6152-6166	3.3	116
176	Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. <i>Current Alzheimer Research</i> , 2016 , 13, 1134-44	3	16
175	Pharmacotherapy of Dementia. <i>Mental Health and Illness Worldwide</i> , 2016 , 1-26	0.1	2
174	Dr Mazereeuw and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, e1006	4.6	
173	Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review. <i>Current Molecular Medicine</i> , 2016 , 16, 137-64	2.5	23

172	Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 373-81	4.3	5
171	Pharmacological interventions for apathy in Alzheimer's disease. <i>The Cochrane Library</i> , 2016 ,	5.2	3
170	P1-190: The Association Between Endothelial Dysfunction and Memory Performance in Patients With Coronary Artery Disease Undertaking Cardiac Rehabilitation 2016 , 12, P476-P477		
169	P1-371: The Association Between Apathy and Executive Function in Coronary Artery Disease Patients is Modified By Endothelial Dysfunction 2016 , 12, P573-P574		
168	P2-403: Targeting MCI with Cardiac Rehabilitation Exercise: A Feasibility Study 2016 , 12, P799-P800		
167	P3-181: Evaluating the Relationship Between Markers of Oxidative Stress and Cognitive Performance in Coronary Artery Disease Patients 2016 , 12, P889-P890		
166	P1-057: Lithium Carbonate and Verbal Memory Improvement in Post-Stroke Patients: Preliminary Report 2016 , 12, P423-P424		
165	Apathy and Attentional Biases in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 837-46	4.3	11
164	Post-stroke depression, obstructive sleep apnea, and cognitive impairment: Rationale for, and barriers to, routine screening. <i>International Journal of Stroke</i> , 2016 , 11, 509-18	6.3	53
163	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1031-1032	1.2	2
162	Caregivers' willingness-to-pay for Alzheimer's disease medications in Canada. <i>Dementia</i> , 2015 , 14, 63-79	3	5
161	White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 754-63	6.5	35
160	Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. <i>Expert Review of Respiratory Medicine</i> , 2015 , 9, 779-99	3.8	13
159	Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease. <i>CNS Drugs</i> , 2015 , 29, 615-23	6.7	39
158	A novel rating scale for the measurement of apathy in institutionalized persons with dementia: the APADEM-NH. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 149-59	6.5	10
157	Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015. <i>International Journal of Stroke</i> , 2015 , 10, 1130-40	6.3	71
156	Latrepirdine for Alzheimer's disease. <i>The Cochrane Library</i> , 2015 , CD009524	5.2	12
155	Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 669-79	4.3	40

154	Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). <i>Canadian Journal of Psychiatry</i> , 2015 , 60, 189-99	4.8	16
153	Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2015 , 34, e290-7	3.4	34
152	A meta-analysis of lipid peroxidation markers in major depression. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 2479-91	3.1	33
151	Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 2309-14	3.1	10
150	Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. <i>PLoS ONE</i> , 2015 , 10, e0134711	3.7	16
149	Cognitive Outcomes following Transcatheter Aortic Valve Implantation: A Systematic Review. <i>Cardiovascular Psychiatry and Neurology</i> , 2015 , 2015, 209569		11
148	Exploring Visual Selective Attention towards Novel Stimuli in Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015 , 5, 492-502	2.5	20
147	Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up study. <i>Biological Psychiatry</i> , 2015 , 77, e13-e14	7.9	7
146	Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, e1424-31	4.6	49
145	Is Cardiac Rehabilitation Exercise Feasible for People with Mild Cognitive Impairment?. <i>Canadian Geriatrics Journal</i> , 2015 , 18, 65-72	2.8	7
144	Assessing cognitive effects of anticholinergic medications in patients with coronary artery disease. <i>Psychosomatics</i> , 2014 , 55, 61-8	2.6	17
143	Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. <i>Pediatrics</i> , 2014 , 133, 1031-7	7.4	38
142	Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. <i>Journal of Neuroinflammation</i> , 2014 , 11, 119	10.1	7
141	Predictors of readmission to a psychiatry inpatient unit. <i>Comprehensive Psychiatry</i> , 2014 , 55, 426-30	7.3	31
140	Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 48	9	9
139	P4-180: DESIGN OF THE SARTAN-AD TRIAL 2014 , 10, P854-P855		
138	Cardiopulmonary fitness correlates with regional cerebral grey matter perfusion and density in men with coronary artery disease. <i>PLoS ONE</i> , 2014 , 9, e91251	3.7	17
137	Kynurenine and depressive symptoms in a poststroke population. <i>Neuropsychiatric Disease and Treatment</i> , 2014 , 10, 1827-35	3.1	17

136	Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. <i>International Psychogeriatrics</i> , 2014 , 26, 239-46	3.4	34
135	Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, e29-33	3.4	23
134	Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve. <i>Journal of Neurology</i> , 2013 , 260, 2256-61	5.5	22
133	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , 2013 , 9, e96-e105	1.2	57
132	Zinc in depression: a meta-analysis. <i>Biological Psychiatry</i> , 2013 , 74, 872-8	7.9	141
131	Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study. <i>BMC Geriatrics</i> , 2013 , 13, 135	4.1	14
130	Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, S5	9	71
129	Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). <i>American Journal of Geriatric Psychiatry</i> , 2013 , 21, 549-59	6.5	13
128	Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013 , 9, 602-8	1.2	215
127	Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 1611-21	9	35
126	Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 911-29	9	77
125	Interleukin-17 in post-stroke neurodegeneration. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 436-47	9.7	59
124	The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. <i>Journal of Medical Economics</i> , 2013 , 16, 115-24	2.4	15
123	Assessing the validity of a computer-generated cognitive screening instrument for patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1905-12	5	27
122	Higher cortisol predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery disease. <i>Cardiovascular Psychiatry and Neurology</i> , 2013 , 2013, 340342		11
121	Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 917068		30
120	Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 810-6	4.6	122
119	Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease. <i>Canadian Geriatrics Journal</i> , 2013 , 16, 180-5	2.8	9

118	Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 789-97	6.5	76
117	A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 2703-11	5.3	21
116	Effects of Ω fatty acids on cognitive performance: a meta-analysis. <i>Neurobiology of Aging</i> , 2012 , 33, 1482.e17-29	5.6	157
115	Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis. <i>American Heart Journal</i> , 2012 , 163, 666-76.e1-3	4.9	58
114	Computerized cognitive testing for patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 196-201	4	12
113	Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden?. <i>Drugs and Aging</i> , 2012 , 29, 167-179	4.7	27
112	A review of cost-effectiveness of palivizumab for respiratory syncytial virus. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012 , 12, 553-67	2.2	19
111	Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. <i>European Journal of Pediatrics</i> , 2012 , 171, 833-41	4.1	35
110	CARESS. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 213	3.4	3
109	Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, e277-87	4.6	11
108	Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 1	6.5	2
107	Current and emerging drug treatment options for Alzheimer's disease: a systematic review. <i>Drugs</i> , 2011 , 71, 2031-65	12.1	155
106	Memantine in dementia: a review of the current evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 787-800	4	44
105	Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. <i>Ageing Research Reviews</i> , 2011 , 10, 404-12	12	63
104	Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease. <i>Brain, Behavior, and Immunity</i> , 2011 , 25, 1264-71	16.6	32
103	The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. <i>CNS Neuroscience and Therapeutics</i> , 2011 , 17, 411-27	6.8	70
102	A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. <i>Canadian Respiratory Journal</i> , 2011 , 18, e10-9	2.1	57
101	The effects of donepezil on computer-simulated driving ability among healthy older adults: a pilot study. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 587-92	1.7	

100	CARESS: the Canadian registry of palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 651-5	3.4	42
99	Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. <i>Psychosomatic Medicine</i> , 2011 , 73, 580-7	3.7	12
98	Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. <i>International Psychogeriatrics</i> , 2011 , 23, 539-45	3.4	19
97	Long-term use of cholinesterase inhibitors: till death do us part?. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 7-9	2.8	0
96	The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. <i>Journal of Neuroinflammation</i> , 2011 , 8, 17	10.1	65
95	Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. <i>CNS Drugs</i> , 2011 , 25, 425-33	6.7	17
94	Pediatric cancer rates after universal folic acid flour fortification in Ontario. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 60-5	2.9	26
93	Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011 , 24, 67-72	3.8	19
92	Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelae. <i>Current Drug Targets</i> , 2011 , 12, 243-55	3	34
91	Are vascular risk factors associated with post-stroke depressive symptoms?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011 , 24, 215-21	3.8	11
90	Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 1181-8	4.6	73
89	The relationship between inflammatory markers and post stroke cognitive impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010 , 23, 199-205	3.8	73
88	Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. <i>Brain Injury</i> , 2010 , 24, 959-69	2.1	47
87	A meta-analysis of cytokines in major depression. <i>Biological Psychiatry</i> , 2010 , 67, 446-57	7.9	3009
86	A meta-analysis of cytokines in Alzheimer's disease. <i>Biological Psychiatry</i> , 2010 , 68, 930-41	7.9	669
85	Changing costs and the impact on RSV prophylaxis. <i>Journal of Medical Economics</i> , 2010 , 13, 705-8	2.4	18
84	The cost effectiveness of palivizumab: a systematic review of the evidence. <i>Journal of Medical Economics</i> , 2010 , 13, 453-63	2.4	34
83	The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. <i>CNS Drugs</i> , 2010 , 24, 909-27	6.7	37

82	Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 91-9	4.8	43
81	The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 768-75	4.8	22
80	Cardiopulmonary fitness is associated with cognitive performance in patients with coronary artery disease. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 1519-25	5.6	25
79	Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 393-400	3.1	58
78	Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection. <i>Canadian Family Physician</i> , 2010 , 56, 988-91	0.9	1
77	Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 270-9	4.6	154
76	A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1125-30	4.6	29
75	Therapy for Alzheimer's Disease: How Effective are Current Treatments?. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 163-80	6.6	69
74	A SPECT study of sleep disturbance and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 27, 254-9	2.6	14
73	Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. <i>Psychoneuroendocrinology</i> , 2009 , 34, 1560-6	5	38
72	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 1174-6	3.9	4
71	The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. <i>Journal of Medical Economics</i> , 2009 , 12, 361-70	2.4	28
70	Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1631-2; author reply 1632-3	2.5	
69	Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children : a case-control study. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 697-701	3.4	62
68	Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 702-6	3.4	42
67	Factor analysis of the Rivermead Post-Concussion Symptoms Questionnaire in mild-to-moderate traumatic brain injury patients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009 , 21, 181-8	2.7	45
66	A brief history of poststroke depression neuroimaging. <i>Aging Health</i> , 2009 , 5, 79-88		2
65	Benzodiazepine use and driving: a meta-analysis. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 663-73	4.6	87

64	A functional neuroimaging study of appetite loss in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2008 , 271, 97-103	3.2	28
63	Commentary: Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. <i>Experimental Neurology</i> , 2008 , 212, 251-4	5.7	3
62	Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. <i>American Journal of Geriatric Psychiatry</i> , 2008 , 16, 551-7	6.5	28
61	The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. <i>Current Medical Research and Opinion</i> , 2008 , 24, 3223-37	2.5	57
60	Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. <i>Cmaj</i> , 2008 , 179, 787-93	3.5	56
59	An open-label study of citalopram for major depression following traumatic brain injury. <i>Journal of Psychopharmacology</i> , 2008 , 22, 860-4	4.6	55
58	Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. <i>Cmaj</i> , 2008 , 179, 1019-26	3.5	104
57	The serotonin transporter polymorphisms and major depression following traumatic brain injury. <i>Brain Injury</i> , 2008 , 22, 471-9	2.1	26
56	The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. <i>International Psychogeriatrics</i> , 2008 , 20, 1141-59	3.4	17
55	Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 296-301	1.7	94
54	Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery disease. <i>Acta Dermato-Venereologica</i> , 2008 , 40, 213-8	2.2	16
53	A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2007 , 15, 888-98	6.5	33
52	Serotonin-1A receptors in frontotemporal dementia compared with controls. <i>Psychiatry Research - Neuroimaging</i> , 2007 , 156, 247-50	2.9	30
51	A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 116-9	2.6	67
50	Adverse drug events in cognitively impaired elderly patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 395-400	2.6	33
49	A SPECT study of apathy in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 65-72	2.6	87
48	Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. <i>Archives of Neurology</i> , 2007 , 64, 266-72		64
47	Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. <i>Canadian Journal of Psychiatry</i> , 2007 , 52, 248-55	4.8	95

46	Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. <i>Canadian Journal of Psychiatry</i> , 2007 , 52, 630-46	4.8	49
45	Behavioral correlates of GABAergic disruption in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2007 , 19, 151-8	3.4	44
44	Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cholinesterase inhibitors in Alzheimer's disease--evidence-based or evidence-biased?. <i>Alzheimer's and Dementia</i> , 2007 , 3, 177-9	1.2	
43	Management of mild to moderate Alzheimer's disease and dementia. <i>Alzheimer's and Dementia</i> , 2007 , 3, 355-84	1.2	58
42	The contribution of neuropsychiatric symptoms to the cost of dementia care. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 972-6	3.9	167
41	Perceptions of natural health products among patients attending a memory clinic. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006 , 21, 156-63	2.5	9
40	Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?. <i>Drug Safety</i> , 2006 , 29, 833-43	5.1	33
39	Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 803-9	2.9	132
38	Do atypical antipsychotics cause stroke?. <i>CNS Drugs</i> , 2005 , 19, 91-103	6.7	113
37	Dr. Herrmann and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2005 , 162, 1027-a-1028	11.9	0
36	Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. <i>BMJ, The</i> , 2005 , 331, 1169	5.9	697
35	Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2005 , 8, 15	11.1	
34	Erectile dysfunction in spinal cord injury: a cost-utility analysis. <i>Journal of Rehabilitation Medicine</i> , 2005 , 37, 358-64	3.4	22
33	Atypical antipsychotics and risk of cerebrovascular accidents. <i>American Journal of Psychiatry</i> , 2004 , 161, 1113-5	11.9	225
32	The role of norepinephrine in the behavioral and psychological symptoms of dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004 , 16, 261-76	2.7	71
31	Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. <i>Journal of Psychopharmacology</i> , 2004 , 18, 215-20	4.6	21
30	Medial temporal hypoperfusion and aggression in Alzheimer disease. <i>Archives of Neurology</i> , 2004 , 61, 1731-7		39
29	Growth hormone response to clonidine predicts aggression in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2004 , 29, 1192-7	5	19

28	The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. <i>Expert Opinion on Drug Safety</i> , 2004 , 3, 425-40	4.1	73
27	GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. <i>Canadian Journal of Psychiatry</i> , 2004 , 49, 439-53	4.8	140
26	The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach. <i>CNS Drugs</i> , 2003 , 17, 1045-57	6.7	17
25	Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. <i>Journal of Psychiatry and Neuroscience</i> , 2003 , 28, 13-26	4.5	30
24	Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. <i>Cmaj</i> , 2003 , 169, 557-64	3.5	95
23	Central serotonergic activity is related to the aggressive behaviors of Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2002 , 27, 646-54	8.7	32
22	Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 531-41	3.9	42
21	Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. <i>Pediatric Infectious Disease Journal</i> , 2002 , 21, 512-8	3.4	51
20	Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. <i>Drugs and Aging</i> , 2002 , 19, 879-86	4.7	70
19	Role of serotonin in the behavioral and psychological symptoms of dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 5-21	2.7	85
18	Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?. <i>Pharmacotherapy</i> , 2001 , 21, 74-102	5.8	17
17	Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. <i>Journal of Medical Economics</i> , 2001 , 4, 137-156	2.4	22
16	Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. <i>Drugs and Aging</i> , 2001 , 18, 527-50	4.7	22
15	Herbal-drug therapy interactions: a focus on dementia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2001 , 4, 29-34	3.8	32
14	Donepezil for behavioural disorders associated with Lewy bodies: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 338-45	3.9	68
13	Drugs Mimicking Dementia. <i>CNS Drugs</i> , 2000 , 14, 381-390	6.7	5
12	Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. <i>Journal of Clinical Psychiatry</i> , 1998 , 59, 550-61; quiz 562-3	4.6	90
11	Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 692-8	6.1	69

10	Improving the diagnosis of hypersensitivity reactions associated with sulfonamides. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 1228-33	2.9	16
9	Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 564-75	6.1	19
8	Computer-assisted evaluation of adverse events using a Bayesian approach. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 142-7	2.9	25
7	Bayesian evaluation of sequential cases of Neutropenia. <i>Pharmacoepidemiology and Drug Safety</i> , 1993 , 2, S1-S6	2.6	1
6	Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 51, 729-39	6.1	94
5	Advances in the diagnosis of adverse drug reactions. <i>Journal of Clinical Pharmacology</i> , 1992 , 32, 897-904	2.9	64
4	Recent developments in computer-assisted diagnosis of putative adverse drug reactions. <i>Drug Safety</i> , 1991 , 6, 315-22	5.1	8
3	A Bayesian assessment of idiosyncratic adverse reactions to new drugs: Guillain-Barré syndrome and zimeldine. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 174-80	2.9	18
2	The Bayesian differential diagnosis of neutropenia associated with antiarrhythmic agents. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 1120-7	2.9	20
1	Management of behavioural and psychological symptoms of dementia and acquired brain injury	187-216	4